An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of MabThera (rituximab) in combination with methotrexate in synovial tissue and in peripheral blood of patients with active rheumatoid arthritis.

Trial Profile

An open-label, exploratory study of the pharmacokinetic and pharmacodynamic activity of MabThera (rituximab) in combination with methotrexate in synovial tissue and in peripheral blood of patients with active rheumatoid arthritis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2014

At a glance

  • Drugs Rituximab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jul 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 17 Dec 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top